OH SB301

Reclassifies five synthetic cathinones (Methylone, MDPV, Mephedrone, 4-methoxymethcathinone, 4-fluoromethcathinone, 3-fluoromethcathinone) from Schedule I hallucinogens to Schedule I stimulants under state drug schedules.

Establishes licensing requirements for pain management clinics as Category III terminal distributors of dangerous drugs, requiring clinics to be owned and operated solely by physicians and comply with state medical board rules on operations and staffing.

Increases subpoena compliance timeframe from three to seven calendar days for the state dental board's investigative panel and allows summary suspension of dental licenses without prior hearing when there is clear and convincing evidence of violation and immediate danger to public health.

Limits prescriber-furnished controlled substances to 2,500 dosage units per 30-day period and 72-hour supply limits, with exceptions for methadone and buprenorphine used for addiction treatment and clinical research.

Expands state medical board enforcement authority to inspect pain management clinics, establishes new disciplinary grounds including failure to comply with pain management clinic standards, and requires drug database reporting by prescribers who personally furnish controlled substances.